Department of Error (DOI:10.1016/S0140-6736(09)62003-1);Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial

The Lancet

Volumn 375, Issue 9708, 2010, Pages 56-66

  Liang, Xiao Feng ^a   Wang, Hua Qing ^a   Wang, Jun Zhi ^b   Fang, Han Hua ^b   Wu, Jiang ^a   Zhu, Feng Cai ^c   Li, Rong Cheng ^d   Xia, Sheng Li ^e   Zhao, Yu Liang ^f   Li, Fang Jun ^g   Yan, Shao Hong ^h   Yin, Wei Dong ⁱ   An, Kang ^j   Feng, Duo Jia ^k   Cui, Xuan Lin ^j   Qi, Feng Chun ^l   Ju, Chang Jun ^j   Zhang, Yu Hui ^m   Guo, Zhi Jun ⁿ   Chen, Ping Yu ^o   Chen, Ze ^p   Yan, Kun Ming ^q   Wang, Yu ^a   more..

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^c JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Guangxi Autonomous Regional Center for Diseases Control and Prevention   (China)

^e HENAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f Hebei Provincial Center for Disease Control and Prevention   (China)

^g Hunan Provincial Center for Disease Control and Prevention   (China)

^h People's Republic of China   (China)

ⁱ Sinovac Biotech Co Ltd   (China)

^j Sinovac Biotech ^*  (China)

^k China National Biotec Group   (China)

^l Changchun Institute of Biological Products   (China)

^m Jiangsu Yanshen Biological Technology Stock   (China)

ⁿ Zhejiang Tianyuan Bio Pharmaceutical Co Ltd   (China)

^o LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^p Shanghai Institute of Biological Products   (China)

^q Dalian Aleph Biomedical   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; HEMAGGLUTININ; INFLUENZA VACCINE; PLACEBO;

ADULT; ALLERGY; ARTICLE; CHILD; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMAGGLUTINATION; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PANDEMIC; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SKIN INDURATION; SKIN REDNESS; SWELLING; UNSPECIFIED SIDE EFFECT; VIRUS STRAIN;

EID: 72949104686     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60740-4     Document Type: Erratum

References (19)

1. CDC. Update: swine influenza A (H1N1) infections-California and Texas, April 2009. MMWR Morb Mortal Wkly Rep 58 (2009) 435-437
2. CDC. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 58 (2009) 400-402
3. WHO. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 84 (2009) 249-257
4. Katz J., Hancock K., Veguilla V., et al. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58 (2009) 521-524
5. Hancock K., Veguilla V., Lu X., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361 (2009) 1945-1952
6. Clark T.W., Pareek M., Hoschler K., et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine-preliminary report. N Engl J Med (2009) 10.1056/NEJMoa0907650 published online Sept 10.
7. Greenberg M.E., Lai M.H., Hartel G.F., et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine-preliminary report. N Engl J Med (2009) 10.1056/NEJMoa0907413 published online Sept 10.
8. Chen H., Wang Y., Liu W., et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis 15 (2009) 1849-1850
9. WHO. Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development. http://www.who.int/csr/resources/publications/swineflu/candidates_X-179a/en/(accessed Aug 31, 2009).
10. WHO. Summary of available candidate vaccine viruses for development of pandemic (H1N1) 2009 virus vaccines. http://www.who.int/csr/resources/publications/swineflu/summary_candidate_vaccine.pdf (accessed Sept 19, 2009).
11. NIAID Division of Microbiology and Infectious Diseases. Adult toxicity table. http://www3.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/toxtables.htm (accessed Aug 31, 2009).
12. NIAID Division of Microbiology and Infectious Diseases. Pediatric toxicity table. http://www3.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/toxtables.htm (accessed Aug 31, 2009).
13. Lin J., Zhang J., Dong X., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006) 991-997
14. Wu J., Fang F.H., Chen J.T., et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 48 (2009) 1087-1095
15. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) (1997), European Agency for the Evaluation of Medicinal Products, London, UK
16. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03) (2004), European Agency for the Evaluation of Medicinal Products, London, UK
17. Bresson J.L., Perronne C., Launay O., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
18. Ehrlich H.J., Müller M., Oh H., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358 (2008) 2573-2584
19. Zhu F.C., Wang H., Fang H.H., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med (2009) 10.1056/NEJMoa0908535 published online Oct 21.